4503 and ALPMY Related Headlines
Go Back- Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
- Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
- "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
- Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study
- IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
- Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
- FDA grants priority review to Astellas-Pfizer cancer drug application
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
- PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
- Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
- Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
- FDA approves PADCEV plus Keytruda for bladder cancer patients
- U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
- Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
- FDA grants priority review to PADCEV plus KEYTRUDA combination for bladder cancer
- PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
- IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
- PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
- Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
- Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
- Astellas Announces Top Management Personnel Change
- PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean G
- Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean G
- Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
4503 and ALPMY Related Press Releases
Go Back- Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company
- Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
- "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
- IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients
- Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
- Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
- Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
- U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
- Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
- PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
- IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
- PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
- Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
- Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
- Astellas Announces Top Management Personnel Change
- PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean G
- Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean G
- Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
